RxDoctor Payments Data

Ryan Watson, MD

Interventional Cardiology · Jefferson Hills, PANPI 1578977898

Payments from drug & device makers

$20,759in general payments, 2019–2025

Across 241 payments — averaging $86.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$10K
  • Abbott$3K
  • Edwards Lifesciences$2K
  • Philips North America LLC$1K
  • Abiomed$1K
  • Amgen$456
  • plus $4K from 26 others

What the payments were for

  • Consulting fees$1,3486%
  • Grants$8,50041%
  • Travel & lodging$1,6388%
  • Food & beverage$9,08944%
  • Education$1831%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,759 in reported general payments places this provider in the 65th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$150,202
Medicare patients
871
Services billed
2,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$104,725
EntrestoSacubitril/Valsartan50$62,190
JardianceEmpagliflozin61$40,829
Repatha SureclickEvolocumab36$29,892
XareltoRivaroxaban26$27,859
BrilintaTicagrelor22$16,255
FarxigaDapagliflozin Propanediol19$11,570
Metoprolol Succinate224$2,505
Atorvastatin Calcium166$1,204
Losartan Potassium102$916
Ezetimibe41$879
Rosuvastatin Calcium42$829
Carvedilol105$722
ClopidogrelClopidogrel Bisulfate87$589
Spironolactone87$540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$54$104,725116 claims
NovartisEntresto$181$62,19050 claims
Boehringer IngelheimJardiance$136$40,82961 claims
Johnson & JohnsonXarelto$143$27,85926 claims
AstraZenecaBrilinta, Farxiga$125$27,82541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Jefferson Hills

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →